

Jennifer Hammond

Discloser Identifier: 1055620

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|--|--------------|--|
| Pfizer | Employment | Self |
| Title: Vice President Additional Information: | | Position Description: Head, Antiviral Development |
| Pfizer | Stock | Self |
| Additional Information: | | |
| Pfizer | Stock Option | Self |
| Additional Information: | | |

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-19

3. **Are you the corresponding author?**

Yes.

a. **Please list the other authors' names here.**

Robert J. Fountaine, Carla Yunis, Dona Fleishaker, Mary Almas, Weihang Bao, Wayne Wisemandle, Mary Lynn Banieki, Victoria M. Hendrick, J. Abraham Simon-Campos, Veselin Kalfov, Rienk Pijpstra, and James M. Rusnak

Certification

I certify that the information provided in this disclosure is complete and accurate.

Mary Almas

Discloser Identifier: 1145724

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|---|------------|--|
| Pfizer Inc. | Employment | Self |
| Title: Statistician Additional Information: Full time employee | | Position Description: Director of Clinical Statistician |

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Mary Lynn Baniecki

Discloser Identifier: 1057411

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|--------------------------------|------------|---|
| Pfizer Inc. | Employment | Self |
| Title: Sr. Director | | Position Description: Sr. Director of translational medicine, Early Clinical Development |
| Additional Information: | | |
| Pfizer Inc. | Stock | Self |
| Additional Information: | | |

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-1

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Weihsng Bao

Discloser Identifier: 702359

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|---|------------|---|
| Pfizer | Employment | Self |
| Title: Senior Director Additional Information: | | Position Description: Statistics |

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Dona Fleishaker

Discloser Identifier: 1145721

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Robert Fountaine

Discloser Identifier: 1145778

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|--|--------------|---|
| Pfizer Inc. | Employment | Self |
| Title: Executive Director Additional Information: | | Position Description: Global Clinical Lead |
| Pfizer Inc. | Stock | Self |
| Additional Information: | | |
| Pfizer Inc. | Stock Option | Self |
| Additional Information: | | |

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Victoria Hendrick

Discloser Identifier: 1057413

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|--|------------|------------------------------|
| Pfizer | Employment | Self |
| Title: Safety Risk Lead Additional Information: | | Position Description: |
| Pfizer | Stock | Self |
| Additional Information: | | |

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Veselin Kalfov

Discloser Identifier: 1145786

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Rienk Pypstra

Discloser Identifier: 1057418

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|--|------------|---|
| Pfizer Inc. | Employment | Self |
| Title: VP Clinical Development, Infectious Diseases Additional Information: full time employed. | | Position Description: Overseeing a portfolio of development programs |
| Pfizer Inc. | Stock | Self |
| Additional Information: | | |

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

James Rusnak

Discloser Identifier: 1057423

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|--|------------------|------------------|
| Pfizer,Inc. | Employment | Self |
| Title: SVP, Chief Development Officer, Internal Medicine and Infectious Diseases Position Description: Additional Information: | | |
| Pfizer,Inc. | Other Securities | Self |
| Security Description: Additional Information: | | |
| Pfizer,Inc. | Stock | Self |
| Additional Information: | | |

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1018681

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|---|----------------|------------------|
| AstraZeneca | Expert Witness | Self |
| Category: Expert Witness Description: Speaker at the prevention symposium in vulnerable patients., Additional Information: | | |
| AstraZeneca | Other | Self |
| Category: Other Description: Speaker: 1st northern regional scientific conference on Pulmonology and Thoracic Surgery, Additional Information: | | |
| AstraZeneca | Other | Self |
| Category: Other Description: Speaker at the symposium new approaches to the prevention of COVID 19 in vulnerable populations Additional Information: | | |
| AstraZeneca | Expert Witness | Self |
| Category: Expert Witness Description: Speaker at the Respiratory Summit. Additional Information: | | |
| AstraZeneca | Other | Self |
| Category: Other Description: Speaker at the conference vulnerable populations in the era of COVID 19 in Mexico. Additional Information: | | |
| AstraZeneca | Other | Self |
| Category: Other Description: Speaker at the HUMANZ meeting Additional Information: | | |
| AstraZeneca | Other | Self |
| Category: Other Description: Speaker during the advisory board, at IDWeek 2022 Additional Information: | | |
| Instituto Científico Pfizer | Other | Self |

| Entity | Type | Interest Held By |
|--|-------|------------------|
| Category: Other Description: Speaker in advisory board Asia: An overview of COVID-19 treatment landscape. Additional Information: | | |
| Instituto Científico Pfizer | Other | Self |
| Category: Other Description: Advisory Board Speaker: COVID-19 Outpatient Therapies Additional Information: | | |
| Instituto Científico Pfizer | Other | Self |
| Category: Other Description: Speaker in advisory board LATAM: An overview of COVID-19 treatment landscape. Additional Information: | | |
| Instituto Científico Pfizer | Other | Self |
| Category: Other Description: Speaker at the Advisory Board: New antiviral therapies for covid-19 Additional Information: | | |
| Instituto Científico Pfizer | Other | Self |
| Category: Other Description: Speaker on the Paxlovid tour Additional Information: | | |
| Instituto Científico Pfizer | Other | Self |
| Category: Other Description: Advisory Board Speaker: Treatment of Outpatients with COVID-19 Additional Information: | | |
| Instituto Científico Pfizer | Other | Self |
| Category: Other Description: Speaker at the Advisory Board: Clinical guidelines for the management of Paxlovid. Additional Information: | | |
| Instituto Científico Pfizer | Other | Self |
| Category: Other Description: Speaker in advisory board Europe: An overview of COVID-19 treatment landscape Additional Information: | | |
| Regeneron Pharmaceuticals | Other | Self |
| Category: Other Description: Speaker at the conference: innovative therapies in COVID-19. Additional Information: | | |

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-19

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Wayne Wisemandle

Discloser Identifier: 1057410

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|--|------------|--|
| Pfizer Inc. | Employment | Self |
| Title: Sr. Director, Statistics | | Position Description: Lead a team of statisticians to design, analyze and report on clinical trials |
| Additional Information: | | |
| Pfizer Inc. | Stock | Self |
| Additional Information: | | |

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Carla Yunis

Discloser Identifier: 738018

Disclosure Purpose: 23-09003 Hammond

Summary of Interests

Company or Organization

| Entity | Type | Interest Held By |
|--|------------|------------------------------|
| Pfizer | Employment | Self |
| Title: Clinical Operations Head Additional Information: | | Position Description: |

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Nirmatrelvir for Vaccinated/Unvaccinated, Outpatient Adults with Covid-19

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.